Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult females, \>=18 years of age;~* inflammatory breast cancer;~* HER2-positive tumors;~* performance status 0-2.~Exclusion Criteria:~* metastases;~* previous treatment with chemotherapy, radiation therapy or hormone therapy for a breast tumor;~* clinically significant cardiovascular disease, or history of thrombotic disorders.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).